M
M. Elizabeth H. Hammond
Researcher at Intermountain Healthcare
Publications - 7
Citations - 3013
M. Elizabeth H. Hammond is an academic researcher from Intermountain Healthcare. The author has contributed to research in topics: Prostate cancer & Proportional hazards model. The author has an hindex of 6, co-authored 7 publications receiving 2477 citations. Previous affiliations of M. Elizabeth H. Hammond include American Society of Clinical Oncology.
Papers
More filters
Journal ArticleDOI
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C. Wolff,M. Elizabeth H. Hammond,Jared N. Schwartz,Karen L. Hagerty,D. Craig Alfred,Richard J. Cote,Mitchell Dowsett,Patrick L. Fitzgibbons,Wedad Hanna,Amy S. Langer,Lisa M. McShane,Soonmyung Paik,Mark D. Pegram,Edith A. Perez,Michael F. Press,Anthony Rhodes,Catharine M. Sturgeon,Sheila E. Taube,Raymond R. Tubbs,Gail H. Vance,Marc J. van de Vijver,Thomas M. Wheeler,Daniel F. Hayes +22 more
TL;DR: A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed and strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria are recommended.
Journal ArticleDOI
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
Kimberly H. Allison,M. Elizabeth H. Hammond,Mitchell Dowsett,Shannon E. McKernin,Lisa A. Carey,Patrick L. Fitzgibbons,Daniel F. Hayes,Sunil R. Lakhani,Mariana Chavez-MacGregor,Jane Perlmutter,Charles M. Perou,Meredith M. Regan,David L. Rimm,W. Fraser Symmans,Emina Torlakovic,Emina Torlakovic,Leticia Varella,Giuseppe Viale,Giuseppe Viale,Tracey Weisberg,Lisa M. McShane,Antonio C. Wolff +21 more
TL;DR: The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose.
Journal ArticleDOI
Estrogen and progesterone receptor testing in breast cancer: American society of clinical oncology/college of American pathologists guideline update
Kimberly H. Allison,M. Elizabeth H. Hammond,Mitchell Dowsett,Shannon E. McKernin,Lisa A. Carey,Patrick L. Fitzgibbons,Daniel F. Hayes,Sunil R. Lakhani,Mariana Chavez-MacGregor,Jane Perlmutter,Charles M. Perou,Meredith M. Regan,David L. Rimm,W. Fraser Symmans,Emina Torlakovic,Emina Torlakovic,Leticia Varella,Giuseppe Viale,Giuseppe Viale,Tracey Weisberg,Lisa M. McShane,Antonio C. Wolff +21 more
TL;DR: The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose.
Journal ArticleDOI
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial.
Li Yan Khor,Kyounghwa Bae,Alan Pollack,M. Elizabeth H. Hammond,David J. Grignon,Varagur Venkatesan,Seth A. Rosenthal,Mark A. Ritter,Howard M. Sandler,Gerald E. Hanks,William U. Shipley,Adam P. Dicker +11 more
TL;DR: This is the first study to establish an association of COX-2 expression with outcome in patients with prostate cancer who have had radiotherapy, and suggests that LTAD might overcome the effects of COx-2 overexpression.
Journal ArticleDOI
MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610.
Li-Yan Khor,Michelle DeSilvio,Tahseen Al-Saleem,M. Elizabeth H. Hammond,David J. Grignon,William Sause,Michael Pilepich,Paul Okunieff,Howard Sandler,Alan Pollack +9 more
TL;DR: The authors evaluated the association between MDM2 expression and local failure, distant metastasis (DM), cause‐specific mortality, and overall mortality in men treated in Radiation Therapy Oncology Group 8610 with radiotherapy, with or without androgen deprivation.